Radius Investigational Drug Elacestrant (RAD1901) Continues

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
597
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017-

-Median PFS was 5.4 months and Clinical Benefit Rate at 24 weeks was 47.4% -

-38% of study patients previously received fulvestrant; 40% received palbociclib or other CDK 4/6 inhibitor; 50% had an ESR1 mutation-

-10 of the 40 patients remain on treatment as of the cutoff date-

-Investor Webcast today at 8:00 pm CT-

WALTHAM, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS ) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration.

There are 40 patients that have been treated at the 400 mg dose in the elacestrant Phase I dose escalation and expansion cohorts. All study participants are heavily pretreated ER+, HER2-negative, advanced breast cancer patients that have received a median of three prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were 6 confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea, dyspepsia and vomiting.

"It is quite encouraging to see the clinical activity with elacestrant in the heavily pretreated advanced patient population, and further therapeutic development is warranted for patients with hormone receptor positive breast cancer", commented Dr. Aditya Bardia, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. 

Radius plans to initiate a Phase 2 clinical study of elacestrant monotherapy, a potentially pivotal study, for women with advanced or metastatic ER+/HER2- breast cancer early in 2018. 

“Patients cycle through and generally do not repeat treatment regimens, limiting treatment options as their disease advances. We are pleased about the potential to offer patients who have progressed or relapsed during their current standard of care with a new treatment option,” said Gary Hattersley, PhD, Chief Scientific Officer. "Radius is committed to developing and to providing breast cancer patients with the next generation of hormonal treatment options, as a single agent and in combination, across all lines of therapy."   

An update on data from the elacestrant FES PET 106 Phase I clinical study in the EU was presented yesterday and demonstrated that elacestrant reduces 18F-FES uptake in patients with advanced ER+ breast cancer who progressed on prior endocrine therapy. The reduction in FES uptake supports elacestrant dose selection for further clinical development and was similar in patients harboring mutant or wildtype ESR-1. Three preclinical poster presentations further highlighting and demonstrating elacestrant activity, as a single agent and in combination with other targeted therapies, will be presented tomorrow morning at SABCS.

Following a strategic review, Radius has decided to discontinue further evaluation of elacestrant for vasomotor symptoms and will focus instead on the continued clinical development of the compound as a potential treatment option in breast cancer.

WEBCAST/CONFERENCE CALL

In conjunction with today's elacestrant Spotlight presentation at SABCS, Radius will host a conference call and live webcast at 8:00 p.m. CT today to discuss the results of the Phase I program as of the cutoff date of October 30, 2017 and provide a company update.

The live webcast titled “ Oncology Program Update from San Antonio Breast Cancer Symposium – 2017” will be available at https://edge.media-server.com/m6/p/ycgfk3pd or by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm .

Conference call information:

Domestic Dial-in Number: (866) 323-7965 International Dial-in Number: (346) 406-0961 Conference ID: 9089206

A replay of the webcast will be available on the company's website, www.radiuspharm.com in the Investor section under Events and Presentations for 7 days following the live webcast.

About Elacestrant (RAD1901) Elacestrant is a selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once daily oral treatment for hormone-receptor positive breast cancer. Elacestrant is currently being investigated for potential use in women with advanced estrogen receptor positive, HER2 negative, breast cancer, the most common form of the disease. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.

Additional information on the clinical trial program of elacestrant (RAD1901) is available on  www.clinicaltrials.gov .

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the progress of abaloparatide-SC in the regulatory process with the EMA, the progress in the development of our product candidates, including abaloparatide-TD, elacestrant (RAD1901) and RAD140, and the potential clinical uses and therapeutic and other benefits of our product candidates, including abaloparatide-TD, elacestrant and RAD140.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we expect to need to raise additional funding, which may not be available; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products and any collaboration agreements failing to be successful; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period ending June 30, 2017 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.  Any such forward-looking statements represent management's estimates as of the date of this press release.  While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.  These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Relations Contact: Alex Fudukidis Email: alex.fudukidis@russopartnersllc.com Phone: 646-942-5632

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 52

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 149

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 202

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 111

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 163

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 64

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 0

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
BD&J's Workplace Recognition Meets Los Angeles Growth Test

Updated Category News Views 58

A workplace award is not a verdict from a jury, but it can still tell you where a law firm is putting its money and attention. BD&J Injury Lawyers landed on the Los Angeles Business Journal's 2026 list of most admired law firms to work for, announced November 18. For a personal-injury practice trying to deepen its footing in a brutally crowded Los Angeles market, that is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading

Top 5 Most Recently Viewed Articles

Delta Air Lines and Taiwan Semiconductor: Earnings Insights

Updated Category News Views 120

Delta Air Lines: Anticipated Earnings Report As we look ahead to the earnings season, all eyes are on Delta Air Lines. Sales projections indicate a modest increase of 0.8%, yet analysts predict a significant downturn of 15.2% in earnings. Despite some downward adjustments from analysts, Delta boasts an impressive history of surprising on earnings. Delta operates multiple...

Continue Reading
Vera Bradley Sees Share Price Decline Amid Revenue Challenges

Updated Category News Views 153

Vera Bradley Experiences Revenue Challenges Amid Market Pressures Vera Bradley, Inc. (NASDAQ: VRA) has recently faced a noteworthy drop in its stock price, which sank by 12.65% in premarket trading. This decline followed the company's second-quarter earnings report that, although it surpassed expectations, revealed that revenue fell short of what analysts had predicted....

Continue Reading
Organon's Q4 Earnings Results: Key Highlights for Investors

Updated Category News Views 188

Understanding Organon's Q4 Earnings Results Organon (NYSE: OGN) has recently shared its earnings report, revealing critical insights that every investor should consider. The report reflects the company's financial health and performance trends over the last quarter, helping stakeholders make informed decisions. Earnings Overview In a notable announcement, Organon reported...

Continue Reading
Expanding Mental Health Services: Ana Deeter Joins Relief

Updated Category News Views 222

Expanding Mental Health Services at Relief Mental Health Relief Mental Health is excited to announce the addition of Ana Deeter, PA-C, to their team at the Northbrook clinic. Deeter, who is a board-certified physician assistant, will enhance the clinic's psychiatric services and offer SPRAVATO® (esketamine) treatment to adults seeking support. A New Specialist for...

Continue Reading
Discover BLUETTI's Cutting-Edge Energy Innovations at CES 2026

Updated Category News Views 245

Revolutionizing Energy Solutions with BLUETTI At this year's CES, BLUETTI, a leader in energy storage solutions, introduced an array of revolutionary products under the theme 'Innovate for All'. These innovations cater to the diverse demands of modern living, providing freedom and resilience for homes, vehicles, and the planet. Key Innovations from BLUETTI As BLUETTI...

Continue Reading